Evidence map›Paper›PMID 27587282›Full record

Trial reportContemporary clinical trials2016

The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale.

Michael B Saddekni, Kenneth G Saag, Tanja Dudenbostel, Suzanne Oparil, David A Calhoun, Sebastian E Sattui, Daniel I Feig, Paul Muntner, David T Redden, Phillip J Foster and 4 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Contemporary clinical trials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Gout and Metabolic Syndrome: a Tangled Web.Current rheumatology reports · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Michael B SaddekniDepartment of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, AL 35294, USA.
Kenneth G SaagDepartment of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, AL 35294, USA.
Tanja DudenbostelDepartment of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, AL, 35294, USA.
Suzanne OparilDepartment of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, AL, 35294, USA.
David A CalhounDepartment of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, AL, 35294, USA.
Sebastian E SattuiDepartment of Medicine, University of Alabama at Birmingham, AL 35294, USA.
Daniel I FeigDepartment of Pediatrics, Division of Nephrology, University of Alabama at Birmingham, AL 35294, USA.
Paul MuntnerDepartment of Epidemiology, University of Alabama at Birmingham, AL 35294, USA.
David T ReddenDepartment of Biostatistics, University of Alabama at Birmingham, AL 35294, USA.
Phillip J FosterDepartment of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, AL 35294, USA.
Elizabeth J RahnDepartment of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, AL 35294, USA.
Stephanie R BiggersDepartment of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, AL 35294, USA.
Peng LiDepartment of Biostatistics, University of Alabama at Birmingham, AL 35294, USA.
Angelo L GaffoDepartment of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, AL 35294, USA. Electronic address: agaffo@uabmc.edu.

Funding

The Effects of Urate Lowering Therapy on Inflammation, Endothelial function, andP50AR060772 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SINGH, JASVINDER A · 2012 to 2021
$12.8M
Mid-Career Investigator Award (for Kenneth G. Saag, MD, MSc)K24AR052361 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SAAG, KENNETH G · 2005 to 2014
$1.7M
NIAMS NIH HHS K24 AR052361NIAMS NIH HHS P50 AR060772
6 · The paper itself

Abstract

backgroundThe association between hyperuricemia and hypertension is controversial. Animal models, epidemiological data, and small clinical trials have favored a causative role for hyperuricemia in hypertension but more studies are necessary to elucidate putative mechanisms, population susceptibility, and potential for urate-lowering therapies (ULT) to decrease blood pressure (BP). PURPOSE: To describe the background and design of the Serum Urate Reduction to Prevent Hypertension (SURPHER) study.

methodsSURPHER is a single center, double-blinded, crossover trial in which participants are randomly assigned to allopurinol (300mg) or placebo. Enrollment focused on adults 18-40years old with baseline systolic blood pressure≥120 and <160mmHg or diastolic blood pressure≥80 and <100mmHg, and serum urate ≥5.0mg/dL or ≥4.0mg/dL for men or women, respectively. SURPHER recruitment targets participants without chronic kidney disease (estimated glomerular filtration rate>60mL/min/1.73m2), and without prior diagnosis of gout or use of ULT to treat gout. The primary outcome is change from baseline in blood pressure assessed by 24hour ambulatory blood pressure monitoring and mechanistic outcomes include changes in endothelial function as measured by flow-mediated dilation, as well as C-reactive protein levels.

resultsSince June 16, 2014 until present, SURPHER is recruiting participants in the city of Birmingham, Alabama. LIMITATIONS: The study aims to enroll otherwise healthy young adults for a pharmacological intervention study with multiple study-related procedures. Challenges related to recruitment are anticipated and multiple strategies for increasing recruitment and retention are planned if necessary.

Indexed as

AdolescentAdultAllopurinolBlack or African AmericanBlood PressureCross-Over StudiesDouble-Blind MethodEndothelium, VascularFemaleGout SuppressantsHumansHyperuricemiaInflammation MediatorsMaleResearch DesignSex FactorsAllopurinolGout SuppressantsInflammation MediatorsUric AcidAllopurinolBlood pressureEndothelial functionHypertensionHyperuricemiaPrehypertensionSerum urateUrate lowering therapy (ULT)Uric acid

Identifiers

PMID27587282
PMCPMC5261071

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.